Overview
CMND market data
Price History
CMND price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$303.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 20.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.61 – $524.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.5 · P/B 1.81.
Company news
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics MarketGlobenewswire Inc · Jul 20, 2026, 1:00 PM
Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treatment Of Post-Traumatic Stress DisorderBenzinga · Jul 20, 2026, 11:57 AM
Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI SolutionBenzinga · Jul 16, 2026, 1:32 PM
CMND stock has given up its prior gain. Clearmind Medicine shares were trading higher after the company announced an update based on their "hands-on" experience from the CMND-100 trial.Benzinga · Jul 13, 2026, 12:53 PM
CORRECTION: Clearmind Medicine shares are trading lower.Benzinga · Jul 13, 2026, 12:26 PM
Clearmind Medicine shares are trading higher after the company announced an update based on their "hands-on" experience from the CMND-100 trial.Benzinga · Jul 13, 2026, 12:24 PM
Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Impression To Treat Alcohol Use DisorderBenzinga · Jul 13, 2026, 12:22 PM
Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Positive Impression To Treat Alcohol Use DisorderBenzinga · Jul 13, 2026, 12:19 PM
Clearmind Medicine Files Response To U.S. Department Of Health And Human Services Request For Information About MEAI's Potential To Treat AddictionBenzinga · Jul 10, 2026, 12:40 PM
Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Treatment For Alcohol Use DisorderBenzinga · Jul 7, 2026, 11:50 AM